158 related articles for article (PubMed ID: 2470107)
21. The biological basis for interleukin-2 anticancer therapy.
Silver HK; Klasa RJ
Prog Clin Biol Res; 1990; 354B():37-52. PubMed ID: 2236173
[No Abstract] [Full Text] [Related]
22. Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity.
Kuribayashi K; Gillis S; Kern DE; Henney CS
J Immunol; 1981 Jun; 126(6):2321-7. PubMed ID: 6164729
[No Abstract] [Full Text] [Related]
23. Interferon treatment of human neoplasia.
Strander H
Adv Cancer Res; 1986; 46():1-265. PubMed ID: 2425561
[No Abstract] [Full Text] [Related]
24. [Biological immunomodulators in the treatment of cancer].
Bello C; Richard C; Hermosa V; Iriondo A; Muruzábal MJ; Pérez Encinas M; Zubizarreta A
Sangre (Barc); 1988 Apr; 33(2):132-43. PubMed ID: 2456623
[No Abstract] [Full Text] [Related]
25. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA
Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
[No Abstract] [Full Text] [Related]
26. Long-term culture of LAK cells: expansion and activation signals.
Ochoa AC; Migliori RJ; Alter BJ; Sondel PM; Simmons RL; Bach FH
Prog Clin Biol Res; 1987; 244():289-99. PubMed ID: 3116557
[TBL] [Abstract][Full Text] [Related]
27. 5-halo-6-phenyl pyrimidinones: new molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells.
Lotzová E; Savary CA; Stringfellow DA
J Immunol; 1983 Feb; 130(2):965-9. PubMed ID: 6848603
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA; Lotze MT
Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
[No Abstract] [Full Text] [Related]
29. In vivo and in vitro activation of NK cytotoxicity with IL-2.
Ibayashi Y; Tokuda Y; Saks ER; Sarna GP; Golub SH
Prog Clin Biol Res; 1987; 244():275-85. PubMed ID: 3498954
[No Abstract] [Full Text] [Related]
30. [Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
Robak T
Pol Tyg Lek; 1988 Nov; 43(47):1491-5. PubMed ID: 3266975
[No Abstract] [Full Text] [Related]
31. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
32. [Interrelations of natural cellular cytotoxicity and interferon systems in immobilization stress].
Sukhikh FT; Nosik NN; Parshina OV; Van'ko LV; Meerson FZ
Biull Eksp Biol Med; 1984 Nov; 98(11):593-5. PubMed ID: 6210120
[TBL] [Abstract][Full Text] [Related]
33. Generation of natural killer-like cytotoxicity from human thymocytes with interleukin-2.
Gray JD; Torten M; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(3):124-33. PubMed ID: 6209571
[TBL] [Abstract][Full Text] [Related]
34. [LAK-adoptive immunotherapy with cytapheresis].
Urushizaki I
Rinsho Ketsueki; 1988 Nov; 29(11):1965-72. PubMed ID: 3266257
[No Abstract] [Full Text] [Related]
35. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
36. In vitro interactions of purified cloned human interferons on NK cells: enhanced activation.
Targan S; Stebbing N
J Immunol; 1982 Sep; 129(3):934-5. PubMed ID: 6180004
[No Abstract] [Full Text] [Related]
37. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor.
Benczur M; Petrányl GG; Pálffy G; Varga M; Tálas M; Kotsy B; Földes I; Hollán SR
Clin Exp Immunol; 1980 Mar; 39(3):657-62. PubMed ID: 6155232
[TBL] [Abstract][Full Text] [Related]
38. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
39. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
40. [Effects of interleukin-2 and lymphokine-activated killer cells on cell cultures and on transplanted tumors (nude mouse) of human pancreatic carcinomas].
Kühl JS; Klapdor R; Bahlo M; Arps H; Dietel M; Mohr M
Beitr Infusionther Klin Ernahr; 1987; 18():261-5. PubMed ID: 3501948
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
